Extended Specialized Assertive Intervention for First Episode Psychosis
First Episode Psychosis of Schizophrenia and Schizotypal DisorderPsychotic Disorders2 moreIn a randomized clinical trial, the researchers want to investigate if the positive short-term outcomes (first 1-2 years), achieved with specialized assertive intervention programme (OPUS), can be maintained for five years if the specialized treatment is sustained over the first five years in comparison to only two years of specialized treatment followed by three years of standard treatment.
A Study of the Effect of Carbamazepine on the Pharmacokinetics of Paliperidone Extended Release...
SchizophreniaBipolar DisorderThe purposes of this study are to evaluate the effects of a potent metabolic enzyme inducer, carbamazepine, on the steady-state pharmacokinetics of orally administered paliperidone ER and to evaluate the safety and tolerability of the treatments in clinically stable patients with a diagnosis of schizophrenia or bipolar I disorder.
A Bioequivalence Study of 15 mg ER OROS Paliperidone
SchizophreniaThe purpose of this study is to evaluate the bioequivalence between the Phase 3 and the to-be-marketed formulations of extended release (ER) OROS paliperidone and to evaluate the effect of food on the highest to be marketed tablet strength. Additionally, the safety and tolerability of the treatments in healthy volunteers will be assessed.
A Study of the Potential Effects of Trimethoprim on the Pharmacokinetics of ER OROS Paliperidone...
SchizophreniaThe purpose of this study is to evaluate the effects of an organic cation transporter inhibitor, trimethoprim, on the pharmacokinetics of orally administered ER OROS paliperidone and to assess the safety and tolerability of the treatments in healthy male volunteers.
Cognitive Training to Improve Work Outcomes in Severe Mental Illness
SchizophreniaBipolar Disorder1 moreThis study will compare the efficacy of two types of supportive treatments for a program called Individual Placement and Support, which helps people with severe mental illnesses find and keep jobs.
Study to Assess the Efficacy, Safety, and Tolerability of AZD8529 in Adult Schizophrenia Patients...
SchizophreniaThe purpose of this study is to determine whether treatment with daily oral dose of AZD8529 40 mg administered over 28 days is safe, well tolerated and improves main symptoms of schizophrenia in adult schizophrenia patients.
Efficacy, Safety, and Tolerability of SPD489 in Adults With Schizophrenia and Predominant Negative...
Schizophrenia and Predominant Negative SymptomsTo explore the efficacy of SPD489, as adjunctive therapy to a stable dose of atypical antipsychotic medication, on negative symptoms in adult subjects with clinically stable schizophrenia and predominant negative symptoms, as measured by the Scale for the Assessment of Negative Symptoms (SANS).
Predictors of Response to Cognitive Remediation in Schizophrenia
SchizophreniaThe purpose of this study is to determine which variables predict improvement on a cognitive training task battery, used for patients with schizophrenia, and to determine the proportion of patients whose performance returns to normal following cognitive training
Aripiprazole Used as Dual Therapy in the Treatement of Patients With Chronic Stable Schizophrenia...
SchizophreniaSchizoaffective DisorderA Multicenter, Double-blind 16 Week Study on the augmentation of atypical antipsychotic with Aripiprazole in patients with Schizophrenia with inadequate response to antipsychotic treatment.
SWitching to Abilify Trial (SWAT)
SchizophreniaTo evaluate the efficacy, safety and tolerance of an 12 and 26-week aripiprazole administration